ICOSavax’s Exciting Breakthrough: Promising Phase 2 Results for IVX-A12 Vaccine Against RSV and HMPV in Older Adults
The Potential of IVX-A12 Vaccine: A Revolutionary Breakthrough in Fighting Infectious Diseases SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) — Icosavax, Inc. (Nasdaq: ICVX) recently announced positive topline interim results from their Phase 2 clinical trial of the combination VLP vaccine candidate IVX-A12. This groundbreaking development brings hope for a new era in the battle against…